Camille Samuels

Camille Samuels

Directeur/Membre du Conseil chez UNITY BIOTECHNOLOGY, INC.

Fortune : 1 504 $ au 30/04/2024

52 ans
Health Technology
Finance
Commercial Services

Profil

Camille (Cami) focuses on healthcare with an emphasis on biotech, medical devices, and consumer health.
Temperamentally an early-stage investor and company helper, Cami currently serves on the board of Cavalry, Iris, Mahzi, Ocelot, Unity (UBX), and is a board observer at Interdict.
She previously served on the board of several exited Venrock portfolio companies, including Corvidia (sold to Novo), RegenXBio (RGNX), and Spirox (owned by Stryker).
Prior to Venrock, Cami was a Managing Director at Versant Ventures where she served on the board (or as a board observer) at many companies including Genomic Health (GHDX/sold to Exact), Jazz (JAZZ), Kythera (KYTH/sold to Allergan), and Novacardia (sold to Merck).
During her early career, Cami worked in corporate development at Genzyme, Millennium Predictive Medicine, and Tularik, and she was a management consultant at LEK.
Cami earned her Bachelor’s degree in Biology from Duke University and an MBA from Harvard Business School (HBS), where she graduated as a Baker Scholar.
She is a Henry Crown Fellow, serves on the Investment Advisory Committee of Mission BioCapital (MBC), and serves on the HBS Global Advisory Board.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
23/04/2024 1 016 ( 0,01% ) 1 504 $ 30/04/2024

Postes actifs de Camille Samuels

SociétésPosteDébut
UNITY BIOTECHNOLOGY, INC. Directeur/Membre du Conseil 01/03/2015
Private Equity Investor 01/05/2014
Directeur/Membre du Conseil -
Consultant / Advisor -
Directeur/Membre du Conseil -
Directeur/Membre du Conseil -
Muse Therapeutics, Inc. Directeur/Membre du Conseil 22/07/2009
Consultant / Advisor -
Tous les postes actifs de Camille Samuels

Anciens postes connus de Camille Samuels

SociétésPosteFin
REGENXBIO INC. Directeur/Membre du Conseil 05/08/2016
░░░░░░░ ░░░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░ ░░░░░░░░░░ ░░░ ░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
Voir l'expérience en détail de Camille Samuels

Formation de Camille Samuels

Harvard Business School Masters Business Admin
Duke University Undergraduate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Camille Samuels

Relations

100 +

Relations au 1er degré

30

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées3
REGENXBIO INC.

Health Technology

UNITY BIOTECHNOLOGY, INC.

Health Technology

STANDARD BIOTOOLS INC.

Health Technology

Entreprise privées25

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Muse Therapeutics, Inc.

Commercial Services

Health Services

Health Technology

Health Technology

Commercial Services

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Services

Health Technology

Finance

Health Technology

Finance

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Camille Samuels
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT